Pakar Kista

Cyst Health, Explained

Breaking News
Cyst Types

Tandem Secures FDA Clearance for Tubeless Insulin Pump

By Salsabila Hartanti November 17, 2026
Tandem Secures FDA Clearance for Tubeless Insulin Pump - tubeless insulin pump
The Mobi tubeless pump is considered the company’s most important commercial catalyst and growth driver, according to analysts at Leerink Partners.

Tandem Diabetes Care has received Food and Drug Administration clearance for its Mobi tubeless automated insulin delivery system, setting the company up for a 2027 launch. The authorization was disclosed on Friday, and it positions the firm to challenge Insulet in the tubeless pump market. Industry watchers see this milestone as a significant step toward broader adoption of tubeless technology.

The Mobi tubeless pump is considered the company’s most important commercial catalyst and growth driver, according to analysts at Leerink Partners. The device replaces the infusion set with a disposable on-body kit, allowing users to choose between a tubed or tubeless pump. They argue that this flexibility could attract patients who prefer a less visible solution.

The firm plans to enter the tubeless pump market next year, following FDA clearance for a new infusion set and cartridge for Mobi, which is cleared for up to seven days of wear. William Blair analysts expect a relatively smooth transition to the tubeless version, with little pause in current Mobi new-customer growth. Their outlook suggests that early adopters will help drive momentum during the initial rollout.

Patients interested in the new product can purchase the tubed Mobi device and later switch to the tubeless infusion set and cartridge when they become available. Leerink analysts predict that patients could migrate from rival devices because of the pump’s compact form factor and easier pharmacy access. This potential shift may also influence prescribing patterns among clinicians.

Read Also: Synchron halts brain implant trials over component delays

The company intends a limited launch before expanding to full commercial availability in the first half of next year. This phased approach will let the organization build manufacturing capacity and update pharmacy contracts.

It will make tubeless supplies available exclusively through pharmacies for customers with pharmacy benefits, with estimated coverage expected for about 50% of insured lives in the United States. Such a distribution model is designed to streamline reimbursement and improve patient access.

The firm expects expansion of Mobi pharmacy coverage both before and after the launch. Leaders believe payers and pharmacy benefit managers view the tubeless system as an important addition to the pharmacy channel.

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2026 Pakar Kista. All rights reserved.